Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis

doi:10.1053/j.gastro.2023.09.004

. 2024 Jan;166(1):1-10.

doi: 10.1053/j.gastro.2023.09.004. Epub 2023 Sep 9.

Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis

Ikuo Hirano¹, Evan S Dellon², Gary W Falk³, Nirmala P Gonsalves¹, Glenn T Furuta⁴, Albert J Bredenoord⁵; ASCENT WORKING GROUP

Collaborators, Affiliations

Collaborators

ASCENT WORKING GROUP:
Alex Straumann⁶, Alain Schoepfer⁷, Joy W Chang⁸, Kathryn Peterson⁹, Nicholas J Talley¹⁰, Luc Biedermann¹¹, Ulrike von Arnim¹², Edoardo Vincenzo Savarino¹³, Christoph Schlag⁶, Barry K Wershil¹⁴, Calies Menard-Katcher¹⁵, Amanda B Muir¹⁶, Joshua B Wechsler¹⁴, Mirna Chehade¹⁷, Jonathan M Spergel¹⁸, Dan Atkins¹⁹, Salvatore Oliva²⁰, Margaret Collins²¹, Nicoleta C Arva²², Guang-Yu Yang²³, Elizabeth T Jensen²⁴, Ekaterina Safroneeva²⁵, Steven Ackerman²⁶, Sandeep K Gupta²⁷, Lia Couras¹⁶, Marc Rothenberg²⁸, David Katzka²⁹, Maria Pletneva³⁰, Benjamin L Wright³¹, Girish Hiremath³², Amy Klion³², Paneez Khoury³³, Stephen Attwood³⁴, Peter Bonis³⁵, Seema Aceves³⁶, Helen M Larsson³⁷, Matteo Ghisa³⁸, Stephan Miehlke³⁹, Tim Vanuytsel⁴⁰, Philip Woodland⁴¹, Thomas Greuter⁴², Fei Li Kuang⁴³

Affiliations

¹ Kenneth C. Griffin Esophageal Center, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
³ Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
⁴ Section of Pediatric Gastroenterology, Digestive Health Institute, Children's Hospital Colorado, Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado.
⁵ Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
⁶ Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
⁷ Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
⁸ Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor.
⁹ Division of Gastroenterology. University of Utah, Salt Lake City.
¹⁰ School of Medicine and Public Health, University of Newcastle, and Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
¹¹ Department of Gastroenterology & Hepatology, University Hospital Zurich, Zurich, Switzerland.
¹² Department of Gastroenterology, Hepatology, and Infectious Diseases, University Hospital Magdeburg, Germany.
¹³ Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
¹⁴ Division of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
¹⁵ Section of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado.
¹⁶ Division of Gastroenterology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia.
¹⁷ Mount Sinai Center for Eosinophilic Disorders, Departments of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁸ Division of Allergy-Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia.
¹⁹ Section of Allergy and Immunology, Children's Hospital Colorado, Aurora.
²⁰ Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, University Hospital, Umberto I Sapienza University of Rome, Italy.
²¹ Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
²² Department of Pathology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
²³ Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
²⁴ Departments of Epidemiology and Prevention and Internal Medicine, Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
²⁵ Institute of Social and Preventive Medicine, University of Bern, Switzerland.
²⁶ Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois, Chicago.
²⁷ Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's of Alabama/University of Alabama, Birmingham.
²⁸ Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
²⁹ Division of Gastroenterology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
³⁰ Department of Pathology, University of Utah, Salt Lake City.
³¹ Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona.
³² Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee.
³³ National Institutes of Allergic and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
³⁴ Department of Health Services Research, Durham University, Durham, United Kingdom.
³⁵ Division of Gastroenterology, Tufts University School of Medicine. Boston, Massachusetts.
³⁶ Division of Allergy and Immunology, Departments of Pediatrics and Medicine, Rady Children's Hospital, San Diego, University of California, San Diego.
³⁷ Department of Otorhinolaryngology & Head and Neck Surgery, NU-Hospital Group/University of Gothenburg, Sahlgrenska Academy, Goteborg, Sweden.
³⁸ Digestive Endoscopy Unit, Division of Gastroenterology, Padua University Hospital, Padua, Italy.
³⁹ Center for Digestive Diseases, Internal Medicine Center, and Center for Esophageal Disorders, University Hospital Eppendorf, Hamburg, Germany.
⁴⁰ Division of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
⁴¹ Blizard Institute, Barts & The London School of Medicine and Dentistry, London, United Kingdom.
⁴² Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; Department of Gastroenterology & Hepatology, University Hospital Zurich, Zurich, Switzerland; Department of Internal Medicine, GZO Zurich Regional Health Center, Wetzikon, Switzerland.
⁴³ Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 37690772
PMCID: PMC10872872 (available on 2025-01-01)
DOI: 10.1053/j.gastro.2023.09.004

Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis

Ikuo Hirano et al. Gastroenterology. 2024 Jan.

. 2024 Jan;166(1):1-10.

doi: 10.1053/j.gastro.2023.09.004. Epub 2023 Sep 9.

Authors

Ikuo Hirano¹, Evan S Dellon², Gary W Falk³, Nirmala P Gonsalves¹, Glenn T Furuta⁴, Albert J Bredenoord⁵; ASCENT WORKING GROUP

Collaborators

ASCENT WORKING GROUP:
Alex Straumann⁶, Alain Schoepfer⁷, Joy W Chang⁸, Kathryn Peterson⁹, Nicholas J Talley¹⁰, Luc Biedermann¹¹, Ulrike von Arnim¹², Edoardo Vincenzo Savarino¹³, Christoph Schlag⁶, Barry K Wershil¹⁴, Calies Menard-Katcher¹⁵, Amanda B Muir¹⁶, Joshua B Wechsler¹⁴, Mirna Chehade¹⁷, Jonathan M Spergel¹⁸, Dan Atkins¹⁹, Salvatore Oliva²⁰, Margaret Collins²¹, Nicoleta C Arva²², Guang-Yu Yang²³, Elizabeth T Jensen²⁴, Ekaterina Safroneeva²⁵, Steven Ackerman²⁶, Sandeep K Gupta²⁷, Lia Couras¹⁶, Marc Rothenberg²⁸, David Katzka²⁹, Maria Pletneva³⁰, Benjamin L Wright³¹, Girish Hiremath³², Amy Klion³², Paneez Khoury³³, Stephen Attwood³⁴, Peter Bonis³⁵, Seema Aceves³⁶, Helen M Larsson³⁷, Matteo Ghisa³⁸, Stephan Miehlke³⁹, Tim Vanuytsel⁴⁰, Philip Woodland⁴¹, Thomas Greuter⁴², Fei Li Kuang⁴³

Affiliations

¹ Kenneth C. Griffin Esophageal Center, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
³ Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
⁴ Section of Pediatric Gastroenterology, Digestive Health Institute, Children's Hospital Colorado, Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado.
⁵ Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
⁶ Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
⁷ Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
⁸ Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor.
⁹ Division of Gastroenterology. University of Utah, Salt Lake City.
¹⁰ School of Medicine and Public Health, University of Newcastle, and Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
¹¹ Department of Gastroenterology & Hepatology, University Hospital Zurich, Zurich, Switzerland.
¹² Department of Gastroenterology, Hepatology, and Infectious Diseases, University Hospital Magdeburg, Germany.
¹³ Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
¹⁴ Division of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
¹⁵ Section of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado.
¹⁶ Division of Gastroenterology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia.
¹⁷ Mount Sinai Center for Eosinophilic Disorders, Departments of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁸ Division of Allergy-Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia.
¹⁹ Section of Allergy and Immunology, Children's Hospital Colorado, Aurora.
²⁰ Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, University Hospital, Umberto I Sapienza University of Rome, Italy.
²¹ Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
²² Department of Pathology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
²³ Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
²⁴ Departments of Epidemiology and Prevention and Internal Medicine, Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
²⁵ Institute of Social and Preventive Medicine, University of Bern, Switzerland.
²⁶ Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois, Chicago.
²⁷ Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's of Alabama/University of Alabama, Birmingham.
²⁸ Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
²⁹ Division of Gastroenterology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
³⁰ Department of Pathology, University of Utah, Salt Lake City.
³¹ Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona.
³² Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee.
³³ National Institutes of Allergic and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
³⁴ Department of Health Services Research, Durham University, Durham, United Kingdom.
³⁵ Division of Gastroenterology, Tufts University School of Medicine. Boston, Massachusetts.
³⁶ Division of Allergy and Immunology, Departments of Pediatrics and Medicine, Rady Children's Hospital, San Diego, University of California, San Diego.
³⁷ Department of Otorhinolaryngology & Head and Neck Surgery, NU-Hospital Group/University of Gothenburg, Sahlgrenska Academy, Goteborg, Sweden.
³⁸ Digestive Endoscopy Unit, Division of Gastroenterology, Padua University Hospital, Padua, Italy.
³⁹ Center for Digestive Diseases, Internal Medicine Center, and Center for Esophageal Disorders, University Hospital Eppendorf, Hamburg, Germany.
⁴⁰ Division of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
⁴¹ Blizard Institute, Barts & The London School of Medicine and Dentistry, London, United Kingdom.
⁴² Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; Department of Gastroenterology & Hepatology, University Hospital Zurich, Zurich, Switzerland; Department of Internal Medicine, GZO Zurich Regional Health Center, Wetzikon, Switzerland.
⁴³ Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 37690772
PMCID: PMC10872872 (available on 2025-01-01)
DOI: 10.1053/j.gastro.2023.09.004

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest These authors disclose the following: Seema Aceves: speaker for Sanofi-Regeneron, consultant for Sanofi-Regeneron and AstraZeneca, research funding from National Institutes of Health, Implicit Biosciences, CURED, and Bristol Meyers Squibb, and patent for oral viscous budesonide; Steven Ackerman: Chief Scientific Officer and consultant for EnteroTrack and Areteia Therapeutics, speakerfor GlaxoSmithKline, and equity in EnteroTrack; Stephen Attwood: consultant/advisory board for AstraZeneca, Dr Falk Pharma, Bristol Myers Squib, GlaxoSmithKline, Regeneron, and 21; Luc Biedermann: advisory board for Abbvie, Amgen, BMS, Falk, Janssen, Pfizer, Lilly, Takeda, Sanofi, and Esocap, and speaker for Takeda, Sanofi, Abbvie, Falk, BMS, and Pfizer; Albert J. Bredenoord: research funding from Nutricia, Norgine, Thelial, Sanofi/Regeneron, SST, and Dr Falk Pharma, and speaker and/or consulting fees from Laborie, Thelial, Medtronic, Dr Falk Pharma, Calypso Biotech, Eupraxia, Aqilion, Alimentiv, Sanofi/Regeneron, Reckitt, and AstraZeneca; Joy W. Chang. consultant for Sanofi-Regeneron; Mirna Chehade consultant for Regeneron, Adare/Ellodi, AstraZeneca, Sanofi, Bristol Myers Squibb, Recludix Pharma, Nexstone Immunology, Allakos, Shire/Takeda, and Phathom, and research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Bristol Myers Squibb, and Danone; Margaret Collins consultant for Allakos, Arena/Pfizer, AstraZeneca, Calypso Biotech, EsoCap Biotech, GlaxoSmithKline, Receptos/Celgene/BMS, Sanofi/Regeneron Pharmaceuticals, Robarts Clinical Trials/Alimentiv, and Shire/Takeda; Evan S. Dellon: research funding from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, and Shire/Takeda, consultant for Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, and Upstream Bio, and educational grants from Allakos, Holoclara, and Invea; Gary W. Falk: research funding from Adare/Ellodi, Allakos, Arena/Pfizer, Celgene/Receptos/BMS, Celldex, Nexeos, Regeneron, and Shire/Takeda, and consultant for Adare/Ellodi, Allakos, Celgene/Receptos/BMS, Nexstone Immunology, Phathom, Regeneron, Sanofi, Shire/Takeda, and Upstream Bio; Glenn T. Furuta: Chief Medical Officer of EnteroTrack and research support from Arena and Holoclara; Matteo Ghisa: consultant/speaker for Aboca, AGPharma, Alfasigma, Dr Falk Pharma, Global Port, Malesci, and Stethos; Nirmala P. Gonsalves: consultant for AstraZeneca, Allakos, Sanofi, Regeneron, BMS, and Knopp, and speakers bureau for Sanofi and Regeneron; Thomas Greuter: consultant for Sanofi-Regeneron, Janssen, BMS, Takeda, Abbvie, and Dr Falk Pharma, travel grants from Dr Falk Pharma and Vifor, speaker fees from Norgine, Amgen, Abbvie, and Sanofi-Regeneron, and unrestricted research grant from Novartis; Sandeep K. Gupta: consultant for Ellodi, BMS, Shire/Takeda, MedScape, PeerView Institute, Focus Medical Communications, and UpToDate, and research support from Allakos, Ellodi, and AstraZeneca; Ikuo Hirano: consultant for Ellodi/Adare, Allakos, Arena, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, Esocap, Gossamer Bio, Nextsone, Parexel/Calyx, Phathom, Regeneron/Sanofi, and Shire/Takeda, grant/research support from Ellodi/Adare, Allakos, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, Sanofi/Regeneron, and Shire/Takeda, and speaker fees from Sanofi and Regeneron; Girish Hiremath: consultant for Regeneron/Sanofi and BMS, consultancy fees from Regeneron/Sanofi, and speaker fees from BMS; Elizabeth T. Jensen: consultant for Jazz Pharmaceuticals, Regeneron-Sanofi, and Target RWE, speaker/faculty fees from American Academy of Allergy, Asthma & Immunology and American Diabetes Association, and grant support from Target RWE; David Katzka: research funding from Shire/Takeda, consultant for Receptos/Celgene/Bristol Myers Squibb; Chris A. Liacouras: speaker for Regeneron, Sanofi, and Abbot, and consultant for Abbott; Calies Menard-Katcher: consultant for Sanofi/Regeneron; Stephan Miehlke: speaker and consultant fees from Dr Falk Pharma and Sanofi-Regeneron; Amanda B. Muir: consultant for Regeneron, AstraZeneca, Nexstone Immunology, grant support for clinical trials from Allakos, and research support from Morphic; Salvatore Oliva: advisory board for Sanofi, Brystol, and Dr Falk Pharma, and consultant fees from Sanofi, Brystol, Dr Falk Pharma, and Medtronic; Kathryn Peterson: consultant for AGA, Alladapt, AstraZeneca, Allakos, Bristol Meyers Squibb, Ellodi, Invea, Lucid, Nexstone, Peerview, Regeneron, Revolo, Takeda, WebMD, research support from AstraZeneca, Allakos, Adare, Regeneron-Sanofi, and Revolo, speake for AGA, Regeneron, Peerview, Takeda, Allakos, and WebMD, grant support (unrestricted) from Allakos and Chobani, and equity in Nexeos Bio; Maria Pletneva: consultant for Allakos; Marc Rothenberg: consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nexstone One, Santa Ana Bio, Bristol Myers Squibb, Astra Zeneca, Pfizer, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint, equity interest in Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nexstone One, and Santa Ana Bio, royalties for reslizumab (Teva Pharmaceuticals) and PEESSv2 (Mapi Research Trust) and from UpToDate, and inventor on patents owned by Cincinnati Children’s Hospital; Ekaterina Safroneeva: consultant for Aptalis Pharma, Celgene, Novartis, and Regeneron Pharmaceuticals; Edoardo Vincenzo Savarino: speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk Pharma, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, and Unifarco, consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr Falk Pharma, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlé, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas, Takeda, and Unifarco, and research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, and Zeta Farmaceutici; Christoph Schlag: consultant and speaker fees for Ellodi/Adare, AstraZeneca, Esocap, Dr Falk Pharma, Regeneron/Sanofi, and Calypso Biotech; Alain Schoepfer: research funding from Swiss National Science Foundation, Swiss EoE foundation, TIGERS, Sanofi-Aventis, Dr Falk Pharma, Pfizer, GSK, and Receptos-BMS, and speaker and consulting fees from Dr Falk Pharma, Receptos-BMS, Ellodi, Gossamer Bio, GSK, Sanofi-Aventis, Pfizer, Takeda, Abbvie, MSD, and Schwabe Pharma; Jonathan M. Spergel: consultant for Allakos, DBV Technologies, Novartis, Regeneron Pharmaceuticals, and Sanofi, grant support from Novartis, AstraZeneca, Regeneron Pharmaceuticals, and Sanofi, and speaker for Peerview and WebMD; Alex Straumann: consultant for AstraZeneca, BMS, Calypso, EsoCap, Falk-Pharma, GSK, and Sanofi; Nicholas J. Talley: nonfinancial support from Norgine and Bristol Myers Squibb, and personal fees from Allakos, Bayer, Planet Innovation, twoXAR, Viscera Labs, Dr Falk Pharma, Sanofi-Aventis, Glutagen, IsoThrive, BluMaiden, Rose Pharma, Intrinsic Medicine, Comvita Mānuka Honey, GlaxoSmithKline Australia, Astra Zeneca, and Alimetry; Tim Vanuytsel: speaker for Abbott, Biocodex, Dr Falk Pharma, Fresenius Kabi, Ipsen, Menarini, Microbiotica, MyHealth, Remedus, Takeda, and Truvion, consultant for Baxter, Dr Falk Pharma, Hamni Pharm, NorthSea Therapeutics, Takeda, VectivBio, and Zealand Pharma, and research grants from Danone, MyHealth, Takeda, and VectivBio; Ulrike von Arnim: speaker and consultancy fees from EsoCap, Abbvie, Galapagos, Takeda, Dr Falk Foundation, Regeneron/Sanofi, Vifor, Amgen, Janssen, MSD, BMS, and Astra Zeneca; Joshua B. Wechsler: consultant for Allakos, Astrazeneca, Regeneron Pharmaceuticals, Sanofi, and Ellodi, grant support for clinical trials from Allakos and Renegeron/Sanofi, and speaker for Regeneron/Sanofi. The remaining authors disclose no conflicts.

Cited by

Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, Klion AD; International Eosinophil Society Clinical Research Interest Group. Khoury P, et al. J Leukoc Biol. 2024 Jul 25;116(2):307-320. doi: 10.1093/jleuko/qiae051. J Leukoc Biol. 2024. PMID: 38457125 Free PMC article. Review.

References

1. Lyons E, Donohue K, Lee JJ. Developing pharmacologic treatments for eosinophilic esophagitis: draft guidance from the United States Food and Drug Administration. Gastroenterology 2019;157:275–277. - PubMed
1. Hirano I, Spechler S, Furuta G, et al. White paper AGA: drug development for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2017;15:1173–1183. - PMC - PubMed
1. Rothenberg ME, Aceves S, Bonis PA, et al. Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol 2012;130:617–619. - PMC - PubMed
1. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017;5:335–358. - PMC - PubMed
1. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology 2020; 158:1776–1786. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- Xenbase

[1] Lyons E, Donohue K, Lee JJ. Developing pharmacologic treatments for eosinophilic esophagitis: draft guidance from the United States Food and Drug Administration. Gastroenterology 2019;157:275–277. - PubMed

[2] Lyons E, Donohue K, Lee JJ. Developing pharmacologic treatments for eosinophilic esophagitis: draft guidance from the United States Food and Drug Administration. Gastroenterology 2019;157:275–277. - PubMed

[3] Hirano I, Spechler S, Furuta G, et al. White paper AGA: drug development for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2017;15:1173–1183. - PMC - PubMed

[4] Hirano I, Spechler S, Furuta G, et al. White paper AGA: drug development for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2017;15:1173–1183. - PMC - PubMed

[5] Rothenberg ME, Aceves S, Bonis PA, et al. Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol 2012;130:617–619. - PMC - PubMed

[6] Rothenberg ME, Aceves S, Bonis PA, et al. Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol 2012;130:617–619. - PMC - PubMed

[7] Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017;5:335–358. - PMC - PubMed

[8] Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017;5:335–358. - PMC - PubMed

[9] Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology 2020; 158:1776–1786. - PMC - PubMed

[10] Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology 2020; 158:1776–1786. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis

Collaborators

Affiliations

Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis

Authors

Collaborators

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Supplementary concepts

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous